Therapeutic proteins and peptides are characteristic by their high biological activity and specificity,but their clinical uses are bottlenecked by their poor stability,short in vivo half-life and immunogenicity[1].One...Therapeutic proteins and peptides are characteristic by their high biological activity and specificity,but their clinical uses are bottlenecked by their poor stability,short in vivo half-life and immunogenicity[1].One typical example is recombinant human interferon alpha(IFN-α),FDA-approved and widely used in treatments of viral diseases and cancer,yet its short plasma half-life(t1/2=2-4 h)necessi-展开更多
文摘Therapeutic proteins and peptides are characteristic by their high biological activity and specificity,but their clinical uses are bottlenecked by their poor stability,short in vivo half-life and immunogenicity[1].One typical example is recombinant human interferon alpha(IFN-α),FDA-approved and widely used in treatments of viral diseases and cancer,yet its short plasma half-life(t1/2=2-4 h)necessi-
